Please note that this meeting will take place as an in-person event in Washington, D.C. and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference. Please see the Registration page for details.

CME credit is available for in-person attendance for the designated sessions. On-demand presentations are not eligible for CME.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program is subject to change. 

[R] – Remote Presentation
*-Short talk selected from proffered abstracts

thursday, october 6, 2022

Welcome and Opening Keynote Address

friday, october 7, 2022

Plenary Session 1: Structural and Chemical Biology of Chromatin Complexes
Plenary Session 2: Epigenetic Driver Mutations and Malignant Transformation
Plenary Session 3: Chromatin Associated RNA and its Modifications in Development and Disease
Plenary Session 4: Histone Modifications in Development and Disease
Proffered Talks I

saturday, october 8, 2022

Plenary Session 5: Chromatin Complexes in Cancer
Proffered Talks II
Plenary Session 6: 3D Genome and Extrachromosomal DNA
Plenary Session 7: Novel Therapeutic Approaches to Target Chromatin/Transcription

Thursday, october 6, 2022

Welcome and Opening Keynote ADDRESS
5:30–6:30 p.m.

Welcome from conference cochairs

Introduction of opening keynote speaker
Howard Y. Chang, Stanford University, Stanford, California

Structure and function of ATP-dependent chromatin remodelers in human cancer
Cigall Kadoch, Dana-Farber Cancer Institute, Boston, Massachusetts

POSTER SESSION A / opening reception
6:30-9 p.m.    

FRIday, OCTOBER 7, 2022

continental breakfast
7-8 A.M.

Plenary Session 1: STRUCTURAL AND CHEMICAL BIOLOGY OF CHROMATIN COMPLEXES
session chair: cynthia wolberger, johns hopkins university, baltimore, maryland
8-9:30 a.m.

Structural basis of chromatin transcription
Lucas Farnung, Harvard Medical School, Boston, Massachusetts

Catalytic and noncatalytic mechanisms of chromatin modifiers
Karim-Jean Armache, New York University Langone Health, New York, New York

Novel inhibitors of histone H2B deubiquitinating enzymes
Cynthia Wolberger, Johns Hopkins University, Baltimore, Maryland

Break
9:30-10 a.m.

Plenary Session 2: epigenetic driver mutations and malignant transformation
session chair: margaret a. goodell, baylor college of medicine, houston, texas
10–11:30 A.m.

DNMT3A in normal and malignant hematopoiesis
Margaret A. Goodell, Baylor College of Medicine, Houston, Texas

Systematic functional screening of chromatin factors identifies strong lineage and disease dependencies in normal and malignant haematopoiesis
Brian Huntly, Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, England, United Kingdom

Transforming chromatin: Oncohistone mutations in pediatric high-grade glioma
Suzanne J. Baker, St. Jude Children’s Research Hospital, Memphis, Tennessee

Lunch (on own)
11:30 a.m.-1 p.m.

Plenary Session 3: chromatin associated rna and its modifications in development and disease
session chair: chuan he, university of chicago, chicago, illinois
1-2:30 p.m.

Chromatin regulation by reversible chromatin-associated RNA methylation
Chuan He, University of Chicago, Chicago, Illinois

Dynamic roles for transfer RNAs in gene regulation and cancer
Sohail Tavazoie, The Rockefeller University, New York, New York

The lncRNA Firre functions as a transcriptional activator from a distance
John L. Rinn, University of Colorado Boulder, Boulder, Colorado

Break
2:30-3 p.m.                          

Plenary session 4: histone modifications in development and disease
session chair: christopher r. vakoc, cold spring harbor laboratory, cold spring harbor, new york
3-4:30 p.m.

Transcriptional dependencies of tuft cell lung tumors
Christopher R. Vakoc, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York

Epigenetic pathways in human health and disease
Shelley L. Berger, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania

Quantitative proteomics for understanding epigenetics cancer mechanisms
Benjamin A. Garcia, Washington University School of Medicine in St. Louis, St. Louis, Missouri

break
4:30-5 p.m.

proffered talks I
session chair: howard y. chang, stanford university, stanford, california
5-6 p.m.

Mutant NPM1 hijacks transcriptional hub to maintain pathogenic gene programs and block differentiation in acute myeloid leukemia*
Xiaotian Zhang, University of Michigan, Ann Arbor, Michigan

Insights into the histone code recognition by the ATAD2B bromodomain*
Margaret Phillips, University of Vermont, Burlington, Vermont

Lineage plasticity dictates responsiveness to anti-GD2 therapy in neuroblastoma*
Nathaniel W. Mabe, Dana-Farber Cancer Institute, Boston, Massachusetts

High-density CRISPR screens reveal mechanisms of chromatin regulation of stemness networks in acute myeloid leukemia*
Karina O. Barbosa Guerra, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California

poster session B / reception
6-8 p.m.

saturday, october 8, 2022

Continental breakfast
7-8 A.M.

Plenary Session 5: chromatin complexes in cancer
session chair: ali shilatifard, northwestern university feinberg school of medicine, chicago, illinois
8-9:30 a.m.

SWI/SNF complexes in development and disease
Diana C. Hargreaves, Salk Institute, La Jolla, California

Principles of epigenetics and chromatin in development and human disease
Ali Shilatifard, Northwestern University Feinberg School of Medicine, Chicago, Illinois

Characterization of the protein-protein interactions involved in DOT1L epigenetic regulation on biochemical, structural and functional level towards developing new therapeutic intervention
Zaneta Nikolovska-Coleska, University of Michigan, Ann Arbor, Michigan

Break
9:30–9:45 a.m.

proffered talks II
session chair: scott a. armstrong, dana-farber cancer institute, boston, massachusetts
9:45-10:45 A.m.

Targeting EP300 and CBP for therapeutic benefit in pediatric solid tumors*
Adam D. Durbin, St. Jude Children’s Research Hospital, Memphis, Tennessee

Single-molecule and single-cell epigenetics: Decoding the epigenome for cancer research and diagnostics*
Efrat Shema, Weizmann Institute of Science, Rehovat, Israel     

A local tumor microenvironment acquired super-enhancer induces an oncogenic driver for efficient growth under oxidative conditions in colorectal carcinoma*
Royce Zhou, Icahn School of Medicine at Mount Sinai, New York, New York

An epigenetic memory of inflammation controls context-dependent lineage plasticity and KRAS-driven tumorigenesis in the pancreas*
Rohit Chandwani, Weill Cornell Medicine, New York, New York

break
10:45–11 A.m.

Plenary Session 6: 3D GENOME AND EXTRACHROMOSOMAL DNA
session chair: howard y. chang, stanford university, stanford, california
11 a.m.-12:30 p.m.

Modeling epigenetic lesions that cause glioma
Bradley E. Bernstein, Dana-Farber Cancer Institute, Boston, Massachusetts

Reading and writing extrachromosomal DNA
Howard Y. Chang, Stanford University, Stanford, California

Ectopic levels of low-complexity domain interactions repress endogenous oncogenic transcription
Shasha Chong, California Institute of Technology, Pasadena, California

Break
12:30–1 p.m.

Plenary Session 7: NOVEL THERAPEUTIC APPROACHES TO TARGET CHROMATIN/TRANSCRIPTION
session chair: arul m. chinnaiyan, university of michigan, ann arbor, michigan
12:45-2:15 p.m.

Therapeutic targeting of MLL complexes in cancer
Scott A. Armstrong, Dana-Farber Cancer Institute, Boston, Massachusetts

Targeting epigenetic regulators of oncogenic transcription factors
Arul M. Chinnaiyan, University of Michigan, Ann Arbor, Michigan

Aberrant transcriptional condensates in cancer: Mechanisms and implications
Liling Wan, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania

closing remarks and departure
2:15 p.m.

Closing remarks
Arul M. Chinnaiyan, University of Michigan, Ann Arbor, Michigan

Times may change slightly as the program develops with the inclusion of short talks from proffered abstracts.